AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17868430
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg b.i.d.
Trial: 20686477
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in daily steady-state AUC(ss) of 1 microg x h/ml
Trial: 10449212
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate aerosol (ISA) 2.5 mg
Trial: 2169714
Drug: nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nedocromil sodium 1% nasal solution (Tilarin, QID, Fisons plc)
Trial: 7449793
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium carbonate
Trial: 23872464
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg APD421
Trial: 23872464
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg APD421
Trial: 23872464
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg APD421
Trial: 21734596
Drug: 3,4-diaminopyridine (3,4-DAP)
DrugBank: Amifampridine (DB11640)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3,4-diaminopyridine (3,4-DAP) 10 mg
Trial: 21734596
Drug: 4-aminopyridine (4-AP)
RxNorm normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (4-AP) 10 mg
Trial: 16169160
Drug: Gabapentin 3200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 3200 mg (1600 mg bid)
Trial: 1800180
Drug: Topical cysteamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cysteamine 0.2% six times a day
Trial: 31415608
Drug: On-demand medication
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand medication
Trial: 3170992
Drug: Allergoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergoid treatment
Trial: 22340224
Drug: Sufentanil 0.2
RxNorm normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.2 µg/kg
Trial: 22340224
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 µg/kg
Trial: 19057893
Drug: Thiamine therapy
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine therapy (3 x 100 mg capsules per day for 3 months)
Trial: 19057893
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 capsules per day for 3 months)
Trial: 19057893
Drug: Thiamine therapy
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine therapy
Trial: 19057893
Drug: Thiamine therapy
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine therapy and Placebo
Trial: 17464511
Drug: Once-daily loratadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily loratadine 10 mg-pseudoephedrine 240 mg sustained release tablets
Trial: 17464511
Drug: Twice-daily loratadine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily loratadine 5 mg-pseudoephedrine 120 mg combination tablets
Trial: 9924909
Drug: Self-administration (S)
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administration (S)
Trial: 7774736
Drug: Low amniotomy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low amniotomy and oxytocin titration (Group B)
Trial: 7774736
Drug: Intra-cervical Foley
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-cervical Foley balloon overnight followed by low amniotomy and oxytocin titration (Group C)
Trial: 2183884
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg twice daily for 1 week)
Trial: 2183884
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg twice daily for 2 weeks)
Trial: 452602
Drug: L-dopa plus
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa plus decarboxylase inhibitors (carbidopa, benserazide)
Trial: 452602
Drug: L-dopa (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (plasma levels)
Trial: 21441783
Drug: RV5 between
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 between doses 1 and 2
Trial: 21441783
Drug: RV5 between
RxNorm normalized name: human-bovine reassortant rotavirus strain G1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV5 between doses 2 and 3
Trial: 19743457
Drug: CoQ10 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 at 2,700 mg/day for 9 months
Trial: 15117088
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg and 20 mg
Trial: 11692016
Drug: Aspirin (n=49)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (n=49)
Trial: 11692016
Drug: Low-dose low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose low-molecular-weight heparin (LMWH) (n=86)
Trial: 11692016
Drug: Both Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both Aspirin and LMWH
Trial: 9515282
Drug: Ramipril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (2.5 mg bid)
Trial: 9515282
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg tid)
Trial: 8410124
Drug: Chemotherapy (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (96 patients)
Trial: 22105591
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg/d
Trial: 28419992
Drug: Extended slow-dose
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended slow-dose transfusion (ESDT), half an SDP unit administered over 4 hours
Trial: 19184428
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide (group A)
Trial: 24220487
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg gabapentin (group B)
Trial: 24220487
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg chlorpromazine (group C)
Trial: 24220487
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dexamethasone (group D)
Trial: 15049988
Drug: Intravesical resiniferatoxin
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical resiniferatoxin (maximum dose of 1 micro mol/L)
Trial: 9149606
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 1,200 mg/d for 4 days prior to exposure and 400 mg on exposure day
Trial: 9149606
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) for 4 days prior to exposure and 400 mg on exposure day
Trial: 2506661
Drug: rt-PA (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (100 mg on day 1, 50 mg on day 2) plus heparin
Trial: 2506661
Drug: rt-PA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rt-PA (50 mg over 8 hours on days 1 and 2) plus heparin
Trial: 2506661
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (rt-PA plus heparin)
Trial: 30555009
Drug: Sedentary individuals
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedentary individuals (regular vigorous exertion <1 day weekly)
Trial: 30555009
Drug: Frequent regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frequent regular vigorous physical exertion (>4 days weekly)
Trial: 28931647
Drug: Dextromethorphan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (various doses)
Trial: 23436259
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg zaleplon
Trial: 23436259
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg zaleplon
Trial: 23436259
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg zaleplon
Trial: 23436259
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zaleplon
Trial: 23436259
Drug: Zaleplon (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon (all doses)
Trial: 21458802
Drug: Intracytoplasmic morphologically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic morphologically selected sperm injection
Trial: 19151570
Drug: Epirubicin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin preparation (FarmorubicinRTU)
Trial: 19151570
Drug: Lyophilized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized formulation of epirubicin (Farmorubicin)
Trial: 15059413
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg, 20 mg, and 10 mg per day for 4 weeks)
Trial: 15059413
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii multiglycoside (TW, 30-60 mg per day)
Trial: 15059413
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA, 5-6 mg per kilogram of body weight per day)
Trial: 15059413
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF, 16-18 mg per kilogram of body weight per day)
Trial: 15059413
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-thyroid drugs and levo-thyroxine)
Trial: 10989721
Drug: Pefloxacin (15-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin (15-20 mg/kg per day bid for 14-28 days) in combination with ceftazidime and amikacin
Trial: 9315494
Drug: Trazodone 150
RxNorm normalized name: traZODone 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 150 mg/d
Trial: 3512419
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir for 42 days
Trial: 3512419
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir for five days followed by placebo for 37 days
Trial: 30527775
Drug: Enoxaparin–warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin–warfarin
Trial: 26916095
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with exemestane plus bevacizumab (E + BEV)
Trial: 24378269
Drug: Cyanoacrylate injection
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanoacrylate injection (GVO)
Trial: 20959009
Drug: Diabetes-specific cognitive
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes-specific cognitive behaviour group therapy
Trial: 8404175
Drug: Theophylline therapy
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline therapy
Trial: 12507187
Drug: High-dose routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose routine therapies
Trial: 2692969
Drug: Etizolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etizolam (0.5 mg twice daily for 5 weeks)
Trial: 2692969
Drug: Alprazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5 mg twice daily for 5 weeks)
Trial: 29955136
Drug: XELIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELIRI regimen (irinotecan 180 mg/m2 on day 1 plus capecitabine 1000 mg/m2 twice daily on days 1-10 of a 14-day cycle)
Trial: 29955136
Drug: Irinotecan monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan monotherapy (irinotecan 180 mg/m2 on day 1 of a 14-day cycle)
Trial: 17998441
Drug: Daily patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily patient reminder to document seizures
Trial: 12468958
Drug: Controlled-release budesonide
RxNorm normalized name: budesonide Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release budesonide (4.5 mg)
Trial: 12468958
Drug: Deuterium-labelled standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterium-labelled standard formulation (4.8 mg)
Trial: 12468958
Drug: Controlled-release budesonide
RxNorm normalized name: budesonide Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release budesonide
Trial: 12468958
Drug: Deuterium-labelled standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterium-labelled standard formulation
Trial: 7710409
Drug: Conventional mandibular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional mandibular block injection
Trial: 27856497
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered ischemia-tolerant MSCs (itMSCs) at a dosage of 1.5×10^6 cells/kg
Trial: 27856497
Drug: Intravenously administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administered ischemia-tolerant MSCs (itMSCs)
Trial: 23512917
Drug: PGX (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGX (15 g day(-1) for 14 weeks)
Trial: 19186713
Drug: Acupuncture twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture twice each day (observation group I)
Trial: 19186713
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received same Chinese drugs and western medicine and electroacupuncture at Jiquan (HT 1), Quchi (LI 11), Hegu (LI 4), Huantiao (GB 30)
Trial: 17577686
Drug: Amyloid A
RxNorm normalized name: Amyloid A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amyloid A protein quantification in fat tissue using ELISA with monoclonal antihuman serum amyloid A antibodies.
Trial: 15464679
Drug: Eptifibatide infusion
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide infusion
Trial: 9752892
Drug: Lisinopril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (5 to 10 mg)
Trial: 7042592
Drug: Ambroxol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (1000 mg/day for 5 days)
Trial: 31419544
Drug: Crisaborole ointment
RxNorm normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crisaborole ointment 2% applied twice daily for 14 days
Trial: 31419544
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control applied twice daily for 14 days
Trial: 31419544
Drug: Crisaborole ointment
RxNorm normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crisaborole ointment 2% applied open-label to all affected areas for 28 days after initial treatment
Trial: 31419544
Drug: Crisaborole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole treatment
Trial: 22464008
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily supportive text messages (n=26)
Trial: 20372874
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (NaCl, 100 mmol/24 h) supplementation during telmisartan treatment
Trial: 20372874
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during telmisartan treatment
Trial: 15934129
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (13 weeks duration)
Trial: 10588467
Drug: Seal oil
RxNorm normalized name: seal oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal oil (20 g per day for 42 days)
Trial: 10588467
Drug: Vegetable oil
RxNorm normalized name: Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable oil (20 g per day for 42 days)
Trial: 9432569
Drug: Heparan sulfate
RxNorm normalized name: heparan sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparan sulfate (100 mg b.i.d.)
Trial: 9432569
Drug: Mesoglycan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan (50 mg b.i.d.)
Trial: 1541143
Drug: Theophylline (Uniphyllin)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (Uniphyllin) 800 mg taken at night for four weeks
Trial: 4021762
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with intensive preoperative irradiation
Trial: 29935909
Drug: General Education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Education DVD on chemotherapy side effects (GE‐DVD)
Trial: 20124256
Drug: Acetylcholinesterase inhibitors
RxNorm normalized name: acetylcholinesterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholinesterase inhibitors (AChIs)
Trial: 20124256
Drug: FDA-approved AD
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA-approved AD or psychiatric medications
Trial: 17646220
Drug: Theophylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (300 mg/d)
Trial: 7557205
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days)
Trial: 7557205
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24)
Trial: 7557205
Drug: Lynestrenol 10
RxNorm normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynestrenol 10 mg/d continuously (Group 2, n = 14)
Trial: 7557205
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Group 3, n = 21)
Trial: 9494149
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg omeprazole
Trial: 28179586
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy (Pre-S CRT, weekly cisplatin 30mg/m2)
Trial: 19663522
Drug: Armodafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (200 mg/day)
Trial: 15486518
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR 75-150 mg/day
Trial: 11573599
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (5.5 microg kg(‐1))
Trial: 7847600
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg nalmefene
Trial: 7847600
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nalmefene
Trial: 2841885
Drug: Fentanyl-group: approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl-group: approximately 0.2 mg/h fentanyl, 2.5 mg/h midazolam, 2 mg/h pancuronium in intermittent doses
Trial: 2841885
Drug: Ketamine-group: about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine-group: about 50 mg/h ketamine and 2.5 mg/h midazolam, 2 mg/h pancuronium
Trial: 31718828
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg/day)
Trial: 31718828
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg/day) and Rosiglitazone (4 mg/day)